Name of Trial/NCT#: 
18F FES-PET/MRI for Tailoring Treatment of Luminal a and Lobular Breast Cancer (FESTA) (NCT05982496)

Eligible patients:
Women age ≥ 18 years with primary Luminal A or ER-positive lobular breast cancer who are candidates for upfront surgery. Additional eligibility criteria can be found here.

Description of Trial/Summary:
This study aims to evaluate whether 18F-fluoroestradiol (FES) PET/MRI, an imaging approach that uses a radiolabeled form of estrogen, can enhance disease staging and inform treatment planning in patients with Luminal A and ER-positive lobular breast cancer eligible for primary surgical intervention. Participants will undergo additional FES-PET/MRI in addition to standard imaging to assess disease extent and to characterize imaging features potentially associated with tumor biology prior to surgery.

Why is this study beneficial?/Important?
Accurate staging of ER-positive lobular breast cancer remains challenging with conventional imaging techniques. This study explores whether FES-PET/MRI can offer a more precise and non-invasive assessment of disease burden while providing insights into intratumoral heterogeneity. Improved imaging characterization may ultimately support more personalized and effective treatment strategies for patients with lobular breast cancer.

Principal Investigator:
Rosa Di Micco, MD

Trial Contact:
Rosa Di Micco, MD
Phone: +39022643 ext 4565
Email: dimicco.rosa@hsr.it

Nicole Rotmensz, MSc
Phone: +39022643 ext 5650
Email: rotmensz.nicole@hsr.it

Trial Location:
IRCCS San Raffaele, Milan, Italy